NIKKEI 225
38,405.38 +351.28 (+0.92%) HANG SENG
18,395.65 +165.45 (+0.91%) CRUDE OIL
77.67 -0.24 (-0.31%) GOLD FUTURES
2,363.90 -2.60 (-0.11%) DOW
38,111.48 -330.02 (-0.86%) Bitcoin GBP
53,812.07 +357.98 (+0.67%)
Oxurion NV (TG4.BE)
| Previous close | 0.0001 |
| Open | 0.0001 |
| Bid | 0.0001 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0001 - 0.0001 |
| 52-week range | 0.0001 - 0.0017 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 15 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireOxurion Receives Transparency Notification from Atlas Special Opportunities LLC
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – May 27, 2024 – 07:00 PM CET (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on May 24, 2024, from Atlas Special Opportunities, LLC indicating that as of May 22, 2024, it held 2,377,763,043 shares of th
- GlobeNewswire
Oxurion Announces Results on the Annual Shareholders’ Meeting of 16 May 2024
Oxurion Announces Results on the Annual Shareholders’ Meeting of 16 May 2024 Leuven, BELGIUM – 23 May, 2024 – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, held its annual shareholders’ meeting on May 16, 2024. The shareholders approved all items on the agenda of the annual shareholders’ meeting. All documents pertaining to the annual shareholders' meeting held on May 16, 2024, can be consulted on Oxurion’s website Oxurion/shareholders.
Globe NewswireInformation on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas Atlas Special Opportunities, LLC has converted 8 convertible bonds in Oxurion resulting in a EUR 200,000 capital increase. This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market opportunities of USD 3-6 billion. Leuven, BELGIUM
